ketoconazole has been researched along with tamoxifen in 43 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (9.30) | 18.7374 |
1990's | 4 (9.30) | 18.2507 |
2000's | 10 (23.26) | 29.6817 |
2010's | 23 (53.49) | 24.3611 |
2020's | 2 (4.65) | 2.80 |
Authors | Studies |
---|---|
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
Barouch-Bentov, R; Brannan, JM; De Jonghe, S; Dye, JM; Einav, S; Herdewijn, P; O'Brien, CM; Prugar, LI; Pu, SY; Rozenski, J; Schor, S; Wouters, R | 1 |
Gao, F; Huang, G; Xiao, J | 1 |
Lyubina, AP; Mironov, VF; Pashirova, TN; Sapunova, AS; Shaihutdinova, ZM; Tatarinov, DA; Terekhova, NV; Voloshina, AD; Zakharova, LY | 1 |
Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 2 |
Pajeva, IK; Wiese, M | 1 |
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Sen, S; Sinha, N | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Arnstein, HR; Cannon, M; Halliwell, B; Smith, C; Wiseman, H | 1 |
Albert, J; Berry, CC; Fay, W; Geller, J; Liu, J | 1 |
Waxman, J | 1 |
Albert, J; Berry, CC; Fay, W; Geller, J; Liu, J; Weis, P | 1 |
Boublil, JL; Cavaglione, G; Kather, R; Namer, M | 1 |
Lennard, MS; Martin, IJ; Tucker, GT; Williams, ML | 1 |
Peterson, ME; Quesenberry, KE; Rosenthal, KL | 1 |
Cripps, MC; Dahrouge, S; Davies, RA; Goel, R; Huan, S; Prosser, A; Soltys, K; Stewart, DJ; Tomiak, E; Yau, J | 1 |
Baldwin, A; Huang, Z; Jounaidi, Y; Waxman, DJ | 1 |
Boustani, M; Chiang, C; Flockhart, D; Han, X; Karnik, S; Li, L; Liu, L; Philips, S; Quinney, SK; Rocha, LM; Subhadarshini, A; Wang, Z; Wu, HY | 1 |
Lammintausta, R; Lehtinen, T; Pelkonen, O; Scheinin, M; Tolonen, A; Turpeinen, M; Uusitalo, J; Vuorinen, J | 1 |
Li, AP; Loretz, C; Utkarsh, D | 1 |
Honda, H; Ito, Y; Kawamoto, T; Morita, O | 1 |
3 review(s) available for ketoconazole and tamoxifen
Article | Year |
---|---|
Current scenario of tetrazole hybrids for antibacterial activity.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Tetrazoles | 2019 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Hormonal aspects of prostatic cancer: a review.
Topics: Adrenalectomy; Castration; Cyproterone; Diethylstilbestrol; Hormones; Humans; Hypophysectomy; Ketoconazole; Male; Middle Aged; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Receptors, Cell Surface; Tamoxifen; Testosterone | 1985 |
1 trial(s) available for ketoconazole and tamoxifen
Article | Year |
---|---|
Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Ketoconazole; Microsomes, Liver; Middle Aged; Postmenopause; Rifampin; Tamoxifen | 2013 |
39 other study(ies) available for ketoconazole and tamoxifen
Article | Year |
---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
Topics: Antiviral Agents; Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Structure-Activity Relationship; Thiazoles | 2018 |
Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Arthrodermataceae; Bacillus cereus; Candida albicans; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Organophosphorus Compounds; Staphylococcus aureus | 2020 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Binding, Competitive; Caco-2 Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoresceins; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Radioligand Assay; Rhodamine 123; Stereoisomerism; Verapamil; Vinblastine | 2002 |
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport, Active; Biomarkers; Cells, Cultured; Drug Interactions; Fluorescent Dyes; Humans | 2003 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
The antioxidant action of ketoconazole and related azoles: comparison with tamoxifen and cholesterol.
Topics: Animals; Antioxidants; Ascorbic Acid; Brain; Cattle; Cholesterol; Ergosterol; Estrogen Antagonists; Ferric Compounds; Iron; Ketoconazole; Lipid Peroxidation; Liposomes; Male; Microsomes, Liver; Phospholipids; Rats; Stilbenes; Tamoxifen | 1991 |
Effect of antiandrogen and/or antiestrogen blockade on human prostate epithelial and stromal cell protein synthesis.
Topics: Dihydrotestosterone; Epithelium; Humans; Ketoconazole; Kinetics; Male; Megestrol; Megestrol Acetate; Prostate; Prostatic Hyperplasia; Protein Biosynthesis; Tamoxifen | 1986 |
Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level.
Topics: Aged; Dihydrotestosterone; Epithelium; Humans; Ketoconazole; Male; Megestrol; Megestrol Acetate; Prostate; Protein Biosynthesis; Tamoxifen | 1987 |
[Cancer of the prostate: new hormone therapies].
Topics: Androgen Antagonists; Cyproterone; Flutamide; Humans; Ketoconazole; Male; Medroxyprogesterone; Megestrol; Neoplasms, Hormone-Dependent; Progestins; Prostatic Neoplasms; Tamoxifen | 1986 |
Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450.
Topics: Adult; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance; Female; Genetic Variation; Humans; Isomerism; Ketoconazole; Male; Microsomes, Liver; Middle Aged; NADP; Proadifen; Tamoxifen | 1994 |
Questions about assays used for estradiol 1-17 beta.
Topics: Adrenal Cortex Neoplasms; Animals; Estradiol; Female; Ferrets; Ketoconazole; Male; Radioimmunoassay; Tamoxifen | 1994 |
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antitrichomonal Agents; Cyclosporine; Dipyridamole; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunosuppressive Agents; Ketoconazole; Male; Metronidazole; Middle Aged; Neoplasms; Pilot Projects; Tamoxifen; Vasodilator Agents | 1997 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Coculture Techniques; Cyclophosphamide; Cytochrome P-450 Enzyme System; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Female; Genetic Therapy; Ifosfamide; Inhibitory Concentration 50; Ketoconazole; Liver; Male; Microsomes, Liver; Models, Chemical; Neoplasms; Procarbazine; Prodrugs; Rats; Tamoxifen; Time Factors; Troleandomycin; Tumor Cells, Cultured | 2003 |
An integrated pharmacokinetics ontology and corpus for text mining.
Topics: Cytochrome P-450 Enzyme System; Data Mining; Databases, Factual; Drug Interactions; Ketoconazole; Midazolam; Pharmacokinetics; Tamoxifen | 2013 |
In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antifungal Agents; Cells, Cultured; Chemical and Drug Induced Liver Injury; Child; Cyclophosphamide; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Estrogen Antagonists; Female; Hepatocytes; Humans; Immunosuppressive Agents; Ketoconazole; Liver; Male; Middle Aged; Protein Isoforms; Tamoxifen; Young Adult | 2016 |
Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics.
Topics: Administration, Oral; Animals; Chlorpromazine; Cholestasis; Cholesterol; Cyclosporine; Diclofenac; Dose-Response Relationship, Drug; Flutamide; Gene Expression; Humans; Imipramine; Inflammation; Ketoconazole; Liver; Methyltestosterone; Oxidative Stress; Rats; Risk Assessment; Sulindac; Tamoxifen; Toxicogenetics | 2017 |